Drug Trial Radar · NCT07246863
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
131
Planned (sponsor's estimate)
Start
Oct 7, 2025
Primary completion
Oct 1, 2029
Study completion Oct 1, 2031
Sponsor
- Lead sponsor
- CatalYm GmbHIndustry
- Sponsor type
- Industry
- First posted
- Nov 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus Visugromab at the higher dose plus Nivolumab with placebo versus double-placebo with Docetaxel, in participants that receive second-line treatment for non-squamous NSCLC after failure of prior first-line treatment including a CPI (checkpoint inhibitor). The trial consists of 3 Parts: an open-label Safety Run-in part (Part A) followed by a subsequent randomized phase 2b part with 4 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).
Conditions
- Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Adult Solid Tumor
Interventions
Visugromab RDE (recommended dose for expansion)Biological
Participants receive Visugromab (RDE) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)
Visugromab 6mg/kgBiological
Participants receive Visugromab (6mg/kg) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)
NivolumabBiological
Participants receive Nivolumab 360mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)
Placebo Saline InfusionOther
Participants receive Saline intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)
DocetaxelDrug
Participants receive Docetaxel 75 mg/m2 intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: up to 36 months
Locations
36 sites in 7 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center)
Birmingham, Alabama · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
NYU Langone Hospital - Long Island
Mineola, New York · Recruiting
NYU Longone Health
New York, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Hospital Esslingen GmbH
Esslingen am Neckar, Baden-Wurttemberg, Germany · Recruiting
Thorax Clinic Heidelberg
Heidelberg, Baden-Wurttemberg, Germany · Recruiting
University Hospital Wuerzburg, Clinic and Polyclinic II for Gastroenterology, Hematology, Internal Oncology, Stem Cell Therapies, Hepatology, Infectiology, Psychosomatics and Rheumatology/ Clinical Immunology
Würzburg, Bavaria, Germany · Recruiting
Evangelical Hospital Bethel, Clinic for Internal Medicine, Hematology/Oncology, Palliative Medicine Johannesstift
Bielefeld, North Rhine-Westphalia, Germany · Recruiting
Clinics Essen-Mitte
Essen, North Rhine-Westphalia, Germany · Recruiting
Foundation Bethanien Moers
Moers, North Rhine-Westphalia, Germany · Recruiting
Local Health Unit of Romagna - Santa Maria delle Croci Hospital of Ravenna, Onco-Hematology Department
Ravenna, Italy · Recruiting
Institute of Romagna for Cancer Research "Dino Amadori" - IRCCS IRST
Forlì, Emilia-Romagna, Italy · Recruiting
Oncology Reference Center
Aviano, Friuli Venezia Giulia, Italy · Recruiting
National Cancer Institute Regina Elena, IRCCS
Rome, Lazio, Italy · Recruiting
European Institute of Oncology (IEO), IRCCS
Milan, Milan, Italy · Recruiting
Institute of Cancer Research and Treatment of Candiolo
Candiolo, Turin, Italy · Recruiting
MED-Polonia, Sp. z o.o. (LLC)
Poznan, Greater Poland Voivodeship, Poland · Recruiting
Sf. Nectarie Oncology Center
Craiova, Dolj, Romania · Recruiting
Clinica Polisano S.R.L
Sibiu, Sibiu County, Romania · Recruiting
SC Oncomed SRL
Timișoara, Timiș County, Romania · Recruiting
University Hospital Lucus Augusti (HULA)
Lugo, Spain · Recruiting
University Hospital of Jaen
Jaén, Andalusia, Spain · Recruiting
Regional University Hospital of Malaga
Málaga, Andalusia, Spain · Recruiting
University Hospital Virgen del Rocio (HUVR)
Seville, Andalusia, Spain · Recruiting
Hospital Quiron Dexeus Barcelona
Barcelona, Barcelona, Spain · Recruiting
Hospital Clinic of Barcelona
Barcelona, Catalonia, Spain · Recruiting
University Hospital Complex of Santiago (CHUS)
Santiago de Compostela, Galicia, Spain · Recruiting
University Hospital of Girona Dr. Josep Trueta
Girona, Girona, Spain · Recruiting
START- Rioja
Logroño, La Rioja, Spain · Recruiting
Clínica Universidad de Navarra
Madrid, Madrid, Spain · Recruiting
University Hospital 12 de Octubre
Madrid, Madrid, Spain · Recruiting
University Hospital HM Sanchinarro
Madrid, Madrid, Spain · Recruiting
University Clinic of Navarra - Pamplona
Pamplona, Navarre, Spain · Recruiting
University Hospital Basel
Basel, Switzerland · Recruiting
Cantonal Hospital Saint Gallen, Clinic of Oncology and Hematology
Sankt Gallen, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.